ReCAPSE: Recurrence from Claims And PROs for SEER Enhancement

ReCAPSE：SEER 增强的索赔和 PRO 的复发

• 批准号: 10601364
• 负责人: Jessica Chubak
• 金额: $ 19.39万
• 依托单位: FRED HUTCHINSON CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-25 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10601364
• 关键词: ReCAPSE; Recurrence; Claims; PROs; SEER

PROJECT SUMMARY The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute serves as a national dashboard for cancer surveillance and is an authoritative resource for cancer incidence and mortality rates. However, the registry lacks information on cancer recurrence, which is a major outcome impacting decisions and policies around management of disease at both the individual and the population levels. The goal of the proposed study is to develop a scalable approach for population-based ascertainment of cancer recurrence with a specific focus on breast cancer. The first (UG3) phase of the study will develop an innovative algorithm for detecting a first recurrence by combining medical claims with patient reported outcomes (PROs). This phase will be conducted in collaboration with the Seattle-Puget Sound SEER registry and will leverage ongoing research agreements with Puget Sound payers. Different algorithms will be developed to allow for flexibility in maximizing sensitivity or specificity. The algorithms will be validated against gold-standard recurrence information based on electronic medical records from two major local providers. Study participants will consistent of stage I-III breast cancer patients diagnosed in 2013–2016 on whom “gold standard” information on recurrence is available. A retrospective case-control design will be employed in which an equal number of recurrent cases and non-recurrent controls at each validation site will be solicited for PROs regarding their recurrence histories. All validation activities will explicitly adjust for missing data resulting from participant non-response to the PRO solicitation. The second (UH3) phase will be conducted in collaboration with the Kentucky Cancer Registry. The algorithms developed in the UG3 phase will be deployed on all Kentucky stage I-III breast cancer diagnoses in 2015–2017 on whom claims data are available. This phase will include a validation against medical records from patients diagnosed at the University of Kentucky Markey Cancer Center over a concurrent period. In this phase, the study team will develop a visual interface for summarizing recurrence risks overall and within specified prognostic subgroups. The interface will allow users to examine representativeness of the patient cohort used to estimate recurrence risks and will also provide estimates that are adjusted for participant non-response. The proposed work will represent a pioneering effort that establish whether medical claims data combined with patient self-report constitute a promising avenue towards determining whether the critical endpoint of cancer recurrence can be added to population-based cancer registries.

项目概要 美国国家癌症研究所的监测、流行病学和最终结果 (SEER) 计划 作为癌症监测的国家仪表板，是癌症的权威资源 然而，登记处缺乏有关癌症复发的信息。 影响疾病管理决策和政策的重大成果 拟议研究的目标是开发一种可扩展的方法。 用于基于人群的癌症复发确定，特别关注乳腺癌。 该研究的第一（UG3）阶段将开发一种创新算法，通过以下方式检测首次复发： 将医疗索赔与患者报告结果 (PRO) 相结合。 与西雅图-普吉特海湾 SEER 注册机构合作，并将利用正在进行的研究 将开发与普吉特海湾付款人的协议，以实现灵活性。 最大化灵敏度或特异性 该算法将根据黄金标准重现进行验证。 信息基于当地两家主要提供商的电子病历。 与 2013-2016 年诊断的 I-III 期乳腺癌患者的“金标准”一致 将采用回顾性病例对照设计来获取有关复发的信息。 将在每个验证站点征求同等数量的经常性病例和非经常性对照 对于 PRO 的重复历史记录，所有验证活动都将针对缺失进行明确调整。 因参与者未响应 PRO 征集而产生的数据 第二 (UH3) 阶段将是。 与肯塔基州癌症登记处合作进行 UG3 开发的算法。 该阶段将应用于 2015 年至 2017 年所有肯塔基州 I-III 期乳腺癌诊断 此阶段将包括根据患者的医疗记录进行验证。 同期在肯塔基大学马基癌症中心确诊。 阶段，研究团队将开发一个可视化界面，用于总体总结复发风险和 在指定的预后子组内，该界面将允许用户检查代表性。 用于估计复发风险的患者队列，还将提供经过调整的估计值 对于参与者没有回应的情况，拟议的工作将是一项开创性的努力。 医疗索赔数据与患者自我报告相结合是否构成一条有希望的途径 确定是否可以将癌症复发的关键终点添加到基于人群的研究中 癌症登记处。